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Background: To gain biological insights into lung metastases from hepatocellular carcinoma (HCC), we compared
the whole-genome sequencing profiles of primary HCC and paired lung metastases.
Methods: We used whole-genome sequencing at 33X-43X coverage to profile somatic mutations in primary HCC
(HBV+) and metachronous lung metastases (> 2 years interval).
Results: In total, 5,027-13,961 and 5,275-12,624 somatic single-nucleotide variants (SNVs) were detected in primary
HCC and lung metastases, respectively. Generally, 38.88-78.49% of SNVs detected in metastases were present in
primary tumors. We identified 65–221 structural variations (SVs) in primary tumors and 60–232 SVs in metastases.
Comparison of these SVs shows very similar and largely overlapped mutated segments between primary and
metastatic tumors. Copy number alterations between primary and metastatic pairs were also found to be closely
related. Together, these preservations in genomic profiles from liver primary tumors to metachronous lung
metastases indicate that the genomic features during tumorigenesis may be retained during metastasis.
Conclusions: We found very similar genomic alterations between primary and metastatic tumors, with a few
mutations found specifically in lung metastases, which may explain the clinical observation that both primary and
metastatic tumors are usually sensitive or resistant to the same systemic treatments.
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Hepatocellular carcinoma (HCC) is one of the most
common cancers worldwide with an estimated 500,000-
1,000,000 new cases per year [1]. It is also one of the few
cancers with an increased incidence rate [2-4]. Although
curative resection or liver transplant is widely adopted
as treatment for HCC [5], a majority of HCC patients
are not amenable to surgical resection due to the extensive
intrahepatic tumor burden or limited donor resources. In
nature, HCC is an invasive tumor and is metastasized
hematogenously and lymphogenously to other organs,
even after its local recurrence. The most common organs* Correspondence: jkimsmc@skku.edu; hoylim@skku.edu
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reproduction in any medium, provided the orof distant metastases include lungs, lymph nodes, bone,
and brain, in particular, with the lung metastasis occurring
in 18-60% of HCC cases [6]. While extrahepatic metasta-
ses are known to occur in HCC patients with an advanced
intrahepatic tumor stage [6,7], the prognosis in patients
with extrahepatic metastases is extremely poor. To im-
prove the prognosis for HCC metastases, we aim to inves-
tigate the genetic signatures of HCC through unbiased
next-generation sequencing (NGS) in this whole genome-
scale systematic study.
Recently, whole genome sequencing of metastatic acral
melanomas and matched primary tumor and adjacent
normal tissues showed high similarity of global gene
copy number alterations, loss of heterozygosity and sin-
gle nucleotide variation in primary and metastasis tissues
[8]. Meanwhile, de novo nonsynonymous coding single-
nucleotide variants (SNVs) were identified in metastatic
lesions from acral melanomas [8]. In addition, recent stud-
ies that identified the clonal populations by sequencing thel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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date the mechanisms of distant metastases [9,10]. Herein,
we sequenced the whole genomes of 4 paired samples
(primary tumor, metachronous lung metastases) obtained
from HCC patients. These selected patients were treatment
naïve at the time of primary HCC surgery and were later
diagnosed with lung metastatic nodules more than 2 years
after the first surgery. We compared the genetic landscape
between primary liver and metastatic lung tumor tissues
and performed an in-depth investigation of the genetic al-




Four patients who were pathologically diagnosed of HCC
and lung metastases were included in this study.
Case #1(441)
A 50-year old man presented with a 9-cm sized mass at
right hepatic lobe. The patient was a HBV carrier and
his liver function was of Child-Pugh classification of A.
The patient underwent right liver lobectomy when
freshly frozen tissue of primary tumor and blood DNA
was collected. The pathologic review of the surgical spe-
cimen revealed Edmonson grade II, tumor necrosis of
10%, microvascular tumor emboli and chronic active
hepatitis with bridging fibrosis in background liver.
Three years later, the patient developed a 2-cm sized
single metastatic nodule in posterior basal segment of
right lower lobe. The patient underwent right lower
lobectomy and the pathologic diagnosis was metastatic
hepatocellular carcinoma. Currently, the patient is in re-
mission without recurrence since lung metastatectomy
for more than 5 years.
Case #2(DD59)
A 46 year-old man presented with a 5.2 × 4.4 cm massive
HCC involving S6 and S7. The patient was a hepatitis B
carrier. The patient underwent right hemi-hepatectomy
(tissue procurement of primary tumor). The pathologic
features were as follows, Edmonson grade II, 0% necrosis,
intrahepatic metastasis, segmental portal vein microinva-
sion and negative resection margin. Three months later,
the patient developed small recurrent tumor in left lateral
segment of left lobe of liver and underwent radiofrequency
ablation and 6 cycles of transcatheter arterial chemoembo-
lization (TACE) thereafter. Shortly after the 6th TACE, two
nodules were detected in right lung. The patient under-
went video-assisted thoracoscopic surgery wedge resection
of right upper apical segment, posterior segment and RLL
lobectomy. The pathologic diagnosis was metastatic hepa-
tocellular carcinoma. Fresh frozen tissues were collected
during the surgery at this time. Seven months later thepatient developed another 2 cm lung metastatic nodule in
right middle lobe and underwent metastatectomy. The pa-
tient is currently in remission for 4 years.
Case #3(D473)
A 43-year old male presented with an 11-cm sized
HCC-B (hepatitis B) and underwent right hepatectomy.
The pathologic examination revealed Edmonson grade II
HCC with 10% necrosis, no portal vein invasion with
mild portoperiportal inflammation in background liver
due to chronic hepatitis B. Four months following the
surgical resection, a newly developed enhancing nodule
in S3 of liver was detected which was subsequently
treated with 5 cycles of TACE. Two years from the initial
hepatic resection, a 1 cm nodule in left upper lobe was
detected which was surgically removed with wedge resec-
tion. The tumor specimen was confirmed of metastatic
HCC in lung and freshly frozen tissue was collected at this
time. The patient underwent repeated multiple pulmonary
metastatectomies for recurrent metastatases. The patient
still has slowly progressive, multiple lung metastases
which were refractory to sorafenib and sunitinib. The pa-
tient died of disease ten months later after failing to treat-
ment due to disease progression.
Case #4(D430)
A 51-year old male had a 6.6 c m sized liver mass and
was diagnosed of HCC-B. The patient underwent S6 seg-
mentectomy and the pathologic examination revealed
Edmondson grade II, 60% necrosis, no microvessel or
portal vein invasion and no intrahepatic metastasis. Two
years later, a 14 cm solitary lung nodule was detected in
left lower lobe superior segment which was surgically
resected. Thirty months later, the patient developed mul-
tiple HCC nodules and received ten 10 cycles of TACE.
The patient is still undergoing periodic TACE for mul-
tiple HCCs at the time of this writing. The core informa-
tion is marked with specific notes (Additional file 1:
Table S1 and Additional file 2: Figure S1).
Whole genome sequencing
Using the paired-end sequencing strategy, we simultan-
eously generated 98.90Gb-129.65Gb sequence data from
normal liver tissues, primary HCC tumors, and lung me-
tastases of the 4 patients described above, with the corre-
sponding haploid genome coverage of 33–43 fold at high
coverage >99% (Additional file 1: Table S2A). The wide-
spread somatic alterations were identified throughout the
genome, from somatic single nucleotide variants (SNVs)
and small insertions or deletions (indels) to structural var-
iations (SVs) (Figure 1 and Additional file 1: Table S2F).
We next depicted the whole-genome alterations as Circos
plots, which give visual demonstrations of metastasis-
specific genetic alterations (Figure 1). Subsequently, we
Figure 1 (See legend on next page.)
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Figure 1 Circos plots for the 4 primary tumors and their matched metastases. Outer panels represent somatic SNVs with nonsynonymous
and splice mutations in red, others are in black. Somatic copy number alterations are shown in inner panels (orange histogram, duplications; blue
histogram, deletions). Structural variations are depicted as links in the interior of the plots. Blue link, inter-chromosomal translocations; red link,
intra-chromosomal translocations; purple link, insertions; green link, deletions. Plots of A to H show the variants of primary tumor and metastasis
from each of the 4 cases 441, D430, D473 and DD59 with “P” for primary and “M” for metastasis.
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number alterations, and structure variations.
Mutation analysis
Alignments to the reference genome with opened gaps
were performed using BWA (http://bio-bwa.sourceforge.
net/bwa.shtml), and SOAPsnv [11] was used to query
SNVs from tumors against matched normal tissues. 3.40-
8.63% of total SNVs were detected in dbSNP (dbSNP132).
These known germline SNPs were excluded from down-
stream analysis. The SNVs were annotated to RefGene and
summarized according to their genetic features (Table 1).
In total, 5,027-13,961 somatic SNVs were detected in HCC
primary tumors and 5,275-12,624 were in lung metastatic
tumors. In addition, most SNVs detected in lung metasta-
ses were also present in primary tumors, ranging from
38.88% to 78.49% across 4 individuals, suggesting that the
major genetic characteristics of tumors might be preserved
during metastasis (Figure 2).
Mutation spectrum
An overview of the mutation spectrum shows that the C:
G > T:A transition rates within the coding regions were
the highest, i.e. 28.96% in primary tumors and 32.10% in
metastases (Figure 3A and Additional file 1: Table S2D),
both of which were higher than those observed at the
whole-genome level (21.71% vs. 22.22%; Figure 3B). In
addition, the second highest mutation type was C:G >A:T
transversion (19.40% vs. 18.27%) which was consistent
with the notion that C:G > A:T transversion is associated
with HBV-positive HCC [12]. Throughout the genetic re-
gions, less mutations of C nucleotides to other nucleotides
were located in the CpG islands, whereas more C:G > T:ATable 1 Summary of somatic SNVs
Categories 441 D430
Primary tumor Metastasis Primary tumor Met
# of somatic SNVs 13,961 12,624 6,208 5
Synonymous 24 26 19
Nonsense 4 3 1
Missense 74 69 23
Splice 5 5 0
UTR 84 76 43
Intron 4,216 3,826 1,911 1
Intergenic 9,554 8,619 4,211 3mutations were found in the non-CpG island regions
(Additional file 1: Table S2B and S2C), which may be ex-
plained by the fact that cytimidines outside of the CpG
islands are easily methylated and mutated. In total, the
transversion rate was significantly higher in metastases
than in primary tumors (52.65% vs. 54.70%; P = 0.0003531)
(Additional file 1: Table S2E). Among 6 classes of transition
and transversion mutations, we observed an average of
2.39% and 4.87% increases in T:A >G:C (P = 8.46e-16)
and C:G >G:C (P < 2.2e-16) transversion, respectively, in
metastasis-specific mutations (Figure 3B and Additional
file 1: Table S2E), which may be caused by microenviron-
ment seeding or effects of chemotherapy [13].
Mutant allele frequency
To delineate possible genetic evolution during metasta-
sis, we carried out an in-depth examination of the muta-
tions of paired primary and metastasis samples. While a
large portion of SNVs were shared by both stages, sig-
nificant differences were observed between the allele fre-
quency of nonsynonymous and splicing-site SNVs in
cancer related genes (i.e. the genes in cancer census gene
database [14] (Figure 4; Fisher’s exact test). For instance,
a nonsense mutation (E304*) in TP53, which regulates
TAT binding, was found in both primary tumors and
metastases of case D473 (Figure 4C and Additional file
1: Table S3), whereas a deleterious missense mutation in
the DNA-binding domain of TP53 (N131D) was only
detected in metastases of case 441 (Figure 4A and
Additional file 1: Table S3). In addition, we found the
similar SNV frequency in a set of oncogenes and
tumor suppressors, such as CBL and MYC, between
primary tumors and metastases. Non-silent mutationsD473 DD59
astasis Primary tumor Metastasis Primary tumor Metastasis
,275 5,027 7,251 5,666 7,652
13 13 11 5 13
0 3 3 0 4
18 22 36 33 45
0 0 0 1 2
30 37 44 44 57
,667 1,680 2,354 1,878 2,543
,547 3,272 4,803 3,705 4,988
Figure 2 The number of somatic mutations detected in primary tumors and metastases. The percentage of mutations shared by
metastases and primary tumors was calculated, and the mutations are summarized into 3 groups: primary tumors, metastases, and
shared mutations.
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solely in the metastasis stage (Figure 4 and Additional
file 1: Table S4). Moreover, we found 9 mutations with
significantly different allele frequency between in pri-
mary tumor and in metastasis. The 8 mutations are lo-
cated in genes KIAA1377, SESN3, MYH4, ZNF613, C5,Figure 3 Comparison of mutational classes between primary tumors
categories of coding mutations are classified from primary tumor and meta
transition and transversion categories are concluded in primary tumor and
blue boxes represent metastasis. Asterisks represent significant difference b
1e-10<P ≤ 1e-3; ***, P ≤ 1e-10).SPEN, MYO9A and DNM3. Of which, MHY4 is in-
volved in tight junction pathway, SESN3 plays a role in
p53 signaling pathway, SPEN is involved in Notch sig-
naling pathway which regulates transcription. Intri-
guingly, multiple mutations of zinc finger proteins
(ZNF) were detected in the metastasis samples; amongand metastasis samples. (A) The transition and transversion
stasis-specific groups. (B) Fraction of overall mutations spanning the
metastasis-specific groups. Red boxes represent primary tumor and
etween primary tumor and metastasis (*, 1e-3<P ≤ 5e-2; **,
Figure 4 Comparison of nonsynonymous and splice mutation frequency between primary tumors and metastases. Each point represents
a somatic single-nucleotide variant (SNV). Allele frequency enrichment was tested using the Fishers’ exact test. Gray dot, shared mutations; orange,
significantly enriched mutations in primary tumors; green, significantly enriched mutations in metastases; purple, primary tumor-specific
mutations; blue, metastasis-specific mutations. SNVs in cancer genes or genes located in cancer-related pathways are labeled with the
corresponding gene names. SNVs in each of the 4 cases show in plots A to D separately.
Ouyang et al. BMC Medical Genomics 2014, 7:2 Page 6 of 13
http://www.biomedcentral.com/1755-8794/7/2these, metastasis-specific genetic mutations of ZNF257
and ZNF682 have been reported to be upregulated in
metastatic cell lines (lung and bone), relative to the
parental line of breast adenocarcinoma [15]. Overall,
mutations in genes that are involved in the cell cycle,
apoptosis, DNA repair, and transcription regulations
were enriched in the metastasis stage (Additional file 1: Table
S10B). On the basis of the allele frequency distributions, wecan focus on the metastasis-specific genetic alterations to
further investigate its underlying mechanisms of lung me-
tastases in HCC. Dissection of the somatic mutations in
primary tumors and metastases shows that the affected
genes are involved in the focal adhesion and gap junction
pathways (Additional file 1: Tables S3, S10A and S10B). In
the future, high-depth sequencing based on our candidate
list may help explore the subclones or key drivers in
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by Sanger sequencing, and 60 mutations were validated
(6 failed to be validated) (Additional file 1: Table S11).
In addition to the mutation frequency, we examined
whether metastasis-derived mutations occur at certain gen-
omic regions. However, we did not find any obvious hyper-
mutation region in any of the 4 trio samples (Additional
file 2: Figure S4). To further investigate the inter-somatic
mutation distance, we compared the inter-somatic muta-
tion distances to the simulated null distributions. The re-
sults show that the observed somatic mutation distances
(<100 kb) were spaced more closely rather than randomly
spotted (Additional file 2: Figures S2 and S3) and that the
mutation events occurred in a similar manner in both pri-
mary and metastatic tumors (Additional file 2: Figure S5).
We also analyzed the inter-somatic mutation distances
across different cancer types, of which data was derived
from public databases (Materials and methods), such as
liver cancer, lung adenocarcinoma, and prostate cancer.
Interestingly, we found that a specific tumor type may de-
velop its own intrinsic mutation distance (Additional file 2:
Figure S5). Together, our findings suggest that the scat-
tered small regions with dense mutations are present in
the cancer genomes and that specific cancer types are asso-
ciated with their own mutation distance.
Short insertions and deletions
We predicted 2,514-4,925 and 4,366-7,968 indels in pri-
mary tumors and metastases, respectively, including a
total of 25/34 (primary tumor/metastasis) events affect-
ing protein coding (18/24 frameshift and 7/10 in-frame)
in 42 genes (Additional file 1: Table S2F). Specifically, a
frameshift insertion in the tumor suppressor RB1 was
detected in both primary tumors and the matched me-
tastases, whereas a metastasis-specific frameshift dele-
tion was detected in the oncogene TFEB. In addition, a
frameshift insertion in WNT5A and an in-frame dele-
tion in DAAM2 were only detected in metastases; both
WNT5A and DAAM2 are involved in the Wnt signaling
pathway (Additional file 1: Table S10C).
Copy number alteration
Copy number alterations (CNAs) in primary tumors and
metastases of 4 cases were detected by comparing with
their respective matched normal samples. From primary
tumors to metastases, the lengths of CNAs were chan-
ged, but the total sizes of CNAs were not significantly
different (Additional file 1: Table S2G). As indicated by
the CNA plots, primary tumors and their matched lung
metastases generated similar global CNA patterns across
4 pairs (Additional file 2: Figure S6). The copy numbers
across the genomes between primary tumors and metas-
tases were found to be positively correlated with each
other with correlation coefficient >0.5 for all 4 cases(Additional file 2: Figure S7), consistent with the conclu-
sion that the genetic characteristics of metastases mostly
originate from primary tumors. The copy numbers of
CNA events were altered from primary tumors to me-
tastases, and these CNAs were annotated to correspond-
ing genes (Additional file 1: Table S7). Specifically, many
CNAs with common regions but different copy number
between primary tumor and metastasis are abserved in
cases DD59 and D473. Such a pattern corresponds to
the low percentage of somatic SNVs preserved in metas-
tases (Figure 2). We found 26 CNA regions (26 deletions
and no amplification) in primary tumors and 235 CNA
regions (173 deletions and 62 amplifications) in metas-
tases. Notably, 11 of the 26 deletions observed in pri-
mary tumors overlapped with 11 deletions in metastases
(Additional file 2: Figure S7 and Additional file 1: Table
S2H). The deletions detected in both primary tumors
and metastases were mainly located in 1p, 4q, 8p, 9p,
9q, 16p, and 21q (Additional file 1: Table S7). By cat-
egorizing tumor-specific CNA regions in metastases, we
found that alterations of oncogenes and tumor suppres-
sors, for instance, tumor suppressor PMS2 and onco-
genes TFPT, ZNF331, and others, may be linked to
metastatic progression (Additional file 2: Figure S7 and
Additional file 1: Table S7). In addition, frequent som-
atic copy number loss in the region spanning the tumor
suppressor genes, CDKN2A and CDKN2B, was also
observed across metastasis samples (Additional file 1:
Table S7) [8].
Structural variation
We used CREST to detect structural variants (SV) in se-
quencing data [16]. We identified 65–221 and 60–232
SVs in primary tumors and metastases, respectively. In-
deed, the large portion of SVs in primary and metastatic
tumors overlapped with each other (Figure 1). We iden-
tified 30 translocations that were only in metastases, 8
translocations that were only in primary tumors, as well
as 30 overlapped translocations (Additional file 1: Table
S2I). Some of the oncogenes and tumor suppressors,
such as TPM3 and ZNF331, which were located in the
breakpoints of somatic SVs, were detected in our study
(Additional file 1: Table S6). Specific mutated genes that
were identified in tumorigenesis pathways are summa-
rized in Additional file 1: Table S10. Specifically, distinct
mutated genes in metastasis, CNTNAP2 and PDCD1LG2,
are the components of the cell adhesion pathway. The
overexpression of CDH13 and AKAP13A, both of which
were found to be truncated in our study, have been re-
ported to correlate with a higher risk of late recurrence of
hepatocellular carcinoma [17,18]. In addition, the CDH13
and PDCD1LG2 genes located at the breakpoints of an
inter-chromosome translocation may cause the CDH13-
PDCD1LG2 fusion.
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To identify genes as “driver” somatic mutations in either
primary tumorigenesis or metastasis process, the genes
with significant higher nonsynonymous mutation rates
against a background were estimated [19]. Tumor sup-
pressors PRF1 and BRCA1, as well as oncogene TFEB,
all of which may play an important role in cancer cell sur-
vival during the progress of metastasis, were predicted as
driver genes only in metastases. WNT5A, PLCB3, and
DAAM2, which can activate or inhibit canonical Wnt sig-
naling, were predicted as metastasis-specific driver genes
(Additional file 1: Table S10F). TP53, a tumor suppres-
sor that was previously reported to be associated with
liver cancer [14], was also weighted as a driver gene and
is recurrently mutant in metastases (Additional file 2:
Figure S2). In addition, we identified that shared muta-
tions between primary tumors and metastases were sig-
nificantly enriched in the pathways of bladder cancer,
pancreatic cancer, non-small cell lung cancer, thyroid
cancer, and melanoma, which implies that the general
progress of different tumor types may be driven by sev-
eral same mutations. The mTOR signaling pathway and
some others were identified to be significant only in pri-
mary tumors (Additional file 1: Table S9A).
By integrating altered genes in primary tumor and spe-
cifically altered genes in metastasis from four cases, we
concluded several cancer and cell migration relevant path-
ways. Altered pathways in primary tumor were Wnt, JAK-
STAT, cell cycle and focal adhesion pathways (Figure 5),
which function in tumor initiation and development.























































Figure 5 Significantly altered pathway in primary tumor. Pathway ana
alteration in several cancer pathways, including (A) Wnt, (B) focal adhesion
somatic SNVs, Indels, CNAs and SVs. Alteration recurrence was referred as n
represented by different colours.included tight junction, focal adhesion and ErbB/MAPK
pathways (Figure 6). Tumor cells in metastasis carried
alterations enabling migration and circulation and de-
rived additional alterations, which may endowi their
ability to clonalize in distant organ and grow as primary
tumor cells [20].
Conclusion
In summary, genetic alteration patterns are very similar
between primary tumor and metastasis of 4 cases (Figure 1,
Additional file 2: Figure S2 and Table 2). For somatic
SNVs, we concluded that 38.88-78.49% mutations de-
tected in primary tumors were preserved in matched
metastases (Figure 2). Also copy number along tumor
genomes are very close correlated between primary tu-
mors and matched metastases, with correlation coeffi-
cients range of 0.51-0.82 (Pearson correlation coefficient)
for 4 cases (Additional file 2: Figure S7). In addition to
SNVs and CNAs, SVs have the similar pattern across 4
pairs with 30.21-74.07% SVs detected in primary tu-
mors preserved in metastases. From all above, we can
approximately conclude that genetic feature in primary
tumor and metastasis of case 441 are the most similar,
and case D430 ranks the second most similar and then
case D473 and case DD59. Specifically on clinical fea-
tures, case 441 had been performed simple treatment with
only liver lobectomy and without any recurrence during
primary tumor developing to metastasis. Case D430 also
underwent simple segmentectomy, however, developed re-
currence after metastasis detected. Both cases of D473



























lysis for primary tumor mutant genes identified significant genomic
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Figure 6 Significantly altered pathway in metastasis. Pathway analysis for metastasis-specific mutant genes identified significant genomic
alteration in multiple cancer/cell migration relevant pathways, including (A) tight junction, (B) ErbB/MAPK and (C) focal adhesion pathway.
Alterations included somatic SNVs, Indels, CNAs and SVs. Alteration recurrence was referred as number of cases harboring a mutant gene.
Alteration types were represented by different colours.
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ent with that percentages of common point mutations be-
tween primary tumor and metastasis are low for these two
cases (Figure 2).
Discussion
HCC is the fifth most common cancer and the third
most common cause of cancer-related deaths worldwide.
It has a high prevalence in Asia, including Korea, due to
endemic hepatitis B virus infection. numerous clinical
trials using cytotoxic chemotherapy or targeted agents
have failed, except sorafenib [21]. While intrahepatic re-
currence is most common, lung metastases are the most
common extrahepatic spread and account for up to 40%
of metastatic HCC [22]. survival of patients with meta-
static HCC is usually less than 1 year [23]. Recently,prolonged median survival durations have been reported
from 6.4 months to 40.7 months following metastasec-
tomies [24]. However, despite advances in therapeutic
strategies, extrahepatic metastasis is still a major impedi-
ment to better prognosis in HCC patients.
In this study, we employed whole-genome sequencing
to profile somatic mutations and structural variations in
primary HCC (HBV+) and their matched metachronous
lung metastases. Several recent studies on HCCs of dif-
ferent etiologies (HBV, HCV, and alcohol) using whole-
genome and exome sequencing have not only confirmed
previously known mutations of β-catenin and TP53 but
also identified novel genetic alterations in genes that are
involved in epigenetic regulation, such as ARID1A,
ARID1B, ARID2, MLL, and MLL3 [12]. Wnt/β-catenin,
p53 signaling, cell cycle, and chromatin remodeling
Table 2 Similarity of genetic alterations in primary
tumors and matched metastases
Statistics 441 D430 D473 DD59
% of met_SSMs preserved
in primary tumor
78.49% 72.55% 53.26% 38.88%
% of met_Indels preserved
in primary tumor
63.64% 100.00% 57.14% 28.57%
Correlation coefficients of
copy numbers between
primary tumor and metastasis
0.69 0.51 0.82 0.53
% of met_SVs preserved in
primary tumor
74.07% 43.08% 67.87% 30.21%
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primary HCC [12]. To the best of our knowledge, this
study is the first to examine the genomic profiles of
matched pairs of primary and metastatic HCC by whole-
genome sequencing.
In summary, comparison of structural variations be-
tween primary and metastatic tumors shows very similar
and largely overlapped mutated segments (Figure 1). In
addition, CNVs in primary and metastatic pairs were
found to be closely related, and 38.88-78.49% of SNVs
detected in primary HCC tumors were also detected in
lung metastases. These preservations in genomic profiles
from liver primary tumors to metachronous lung metas-
tases indicate that the genomic features during tumori-
genesis may be retained during metastasis.
Despite similarities between primary and metastatic
pairs, a few somatic mutations were detected only in
metastatic tumors. Multiple mutations of zinc finger (ZNF)
genes were detected in the metastasis samples, and mu-
tated genes that are involved in apoptosis and transcription
regulations were enriched in metastases (Additional file 1:
Table S10B). The ZNF family represents a large group of
proteins involved in various aspects of transcriptional regu-
lation [25]. It has been reported that there were almost
twice as many ZNF mutated genes in the HBV-positive
hepatitis [26]. In our study, a total of 5 ZNF, namely
ZNF257, ZNF682, ZNF404, ZNF514, and ZNF142, were
mutated in lung metastases from HCC (Additional file 1:
Table S10B). Among these, ZNF257 and ZNF682 were
previously reported to be upregulated in lung and bone
metastases, relative to the primary breast adenocarcinoma,
and were speculated to be putative metastasis genes [15].
In addition, ZNF mutations were found in head and neck
squamous cell carcinoma (HNSCC); therefore, the genetic
changes to these transcriptional regulators have been im-
plicated in the development of HNSCC [27]. Nevertheless,
the functional role of ZNFs in HCC tumorigenesis is yet to
be defined.
In addition, mutations in known cancer gene suppres-
sor TP53 were also detected in our study samples,
including a nonsense mutation (E343*) in the regulatorof TAT binding and a missense mutation (N131D) in the
DNA-binding domain, both were previously reported
by COSMIC (http://cancer.sanger.ac.uk/cancergenome/
projects/cosmic/) (Additional file 1: Table S3).
Notably, a frameshift insertion in WNT5A and an in-
frame deletion in DAAM2 were detected only in lung
metastases; both WNT5A and DAAM2 are involved in
the Wnt signaling pathway. Recent genome sequencing
studies have revealed that the WNT signaling pathway is
the most frequently altered oncogenic pathway in pri-
mary HCC [12]. In addition to the high prevalence of
CTNNB1 mutations, genetic alterations of other compo-
nents, such AXIN1, AXIN2, and APC genes that encode
proteins containing the destruction box, also occur at a
lower frequency. Wnt5a, which is up-regulated in poorly
differentiated and highly motile mesenchymal-like HCC
cells, has been suggested to play a role in tumor progres-
sion by inducing epithelial mesenchymal transition [28].
In line with this, Wnt5a up-regulation was significantly
shown to enhance migration, proliferation, and invasive-
ness in pancreatic cancer cells in vitro [29]. Importantly,
Wnt signaling has been implicated in the activation of
HCC-initiating cells [30,31]. While Wnt5a has been
described as a tumor promoter in melanoma, gastric,
pancreatic, and prostate cancers, it was suggested to be
a tumor suppressor in HCC, neuroblastoma, leukemia,
colon, and thyroid cancers [32]. The functional signifi-
cance of Wnt5 aberrations in tumorigenesis of lung me-
tastases from HCC primary tumors should be evaluated
in subsequent studies.
Synthetically, primary tumor harbored more alterations
located in Wnt, cell cycle, JAK-STAT pathways (Figure 5),
which plays an important role in encoding protein mo-
lecular emphasizing the cell proliferation, apoptosis and
inflammation, as well as focal adhesion pathway. Focal ad-
hesion pathway has been implicated in the cell migration
and initiated metastasis [33]. For metastasis, specific alter-
ations arose in tight junction and focal adhesion pathways
(Figure 6), which enhanced the cell migration mechanism.
In this study, for the first time, the whole-genome se-
quencing profiles of primary HCC and paired lung
metastases were compared. We found similar genomic
alterations between them, with a few mutations that
were found specifically in lung metastases, which may
explain the clinical observation that both primary and
metastatic tumors are usually sensitive or resistant to
the same systemic treatments.
Methods
Tumor specimens and ethical statement
A total of 4 pairs of fresh frozen tumors and adjacent non-
tumor liver tissues containing no necrosis or hemorrhage
were collected from primary HCC patients treated with
curative hepatectomy at the Samsung Medical Center,
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time of lung metastasectomy. This study was approved
by the Institutional Review Board of Samsung Medical
Center, Seoul, Korea.
DNA
Genomic DNA was extracted from sliced tissue speci-
mens using the QIAamp DNA Mini Kit (Qiagen, Hilden,
Germany), respectively.
Library construction and whole-genome sequencing
Qualified genomic DNA samples were randomly fragmen-
ted by Covaris. After ligation of sequencing adapters to
both ends of resulting fragments, successfully adapter-
ligated DNA fragments were purified, and those with an
insert size of approximately 500 bp were selected by elec-
trophoresis. Insert fragments with correct sizes were har-
vested and prepared for cluster amplification by cBot
(Hiseq 2000).
The qualified DNA library was then loaded on Hiseq2000
for high-throughput sequencing, to meet required sequen-
cing depth with 90-bp paired-end reads. Raw image files
were read by the Illumina’s base calling software with de-
fault parameters, and raw data were collected.
Read mapping and somatic variant detection
Sequencing reads from primary and metastatic tumors,
as well as matched normal tissues, were gap-aligned to
the hg19 reference genome by BWA program, followed by
removal of PCR duplicates. Somatic variants in primary
and metastatic tumors were detected by comparing tumor
reads to those of matched normal samples. Somatic muta-
tions in tumors were predicted by SOAPsnv (http://soap.
genomics.org.cn/index.html) using a sensitive score thresh-
old. Next, p values were calculated using Fisher’s exact test
for all putative mutation sites, based on the distribution of
read support with high stringent specificity and sensitivity
[11]. For mutations present in dbSNP (which are usually
germline mutations), we removed potential germline muta-
tions existing in database of dbSNP132 for the downstream
analysis. Subsequently, we annotated potential somatic
SNVs by mapping them to RefGene (http://refgene.com/)
using an in-house annotation program.
Indels in tumors were examined through gapped align-
ment not allowing gap located 5 bp to either end of the
mapped reads [11]. From the indel pool, somatic indels
were detected by filtering SNV which was also detected
in adjacent normal samples. Somatic indels with ≤5 sup-
porting reads were filtered for high confidence.
We used in-house software based on the read-depth
method to infer copy number variation in primary and
metastatic tumors. Copy number variants were called
when the copy number in tumors was ≤0.75- or ≥1.25-
fold of that in corresponding normal samples. To inferrecurrently amplified or deleted genomic regions, we
detected the focal copy number segments (≤1Mbp) by
re-implementing the GISTIC algorithm [34] using
copy numbers in 1-kb windows, instead of SNP array
probes as markers. G-scores were calculated for gen-
omic and gene-coding regions, based on the frequency
and amplitude of amplification and deletion affecting
each gene, respectively. A significant CNV region was
defined as having an amplification G-score >0.08 or a
deletion G-score <0.09, corresponding to a p-value
threshold of 0.05 from the permutation-derived null
distribution [34].
We further applied CREST [16] to whole-genome DNA
sequence data obtained from primary and metastatic
tumors to identify candidate structural variants (SV) at
base-pair resolution.
Prediction of driver genes
Driver genes were predicted using in-house software by
re-implementing the algorithm in which driver genes
are the genes with a significant higher non-silent muta-
tion (nonsynonymous/splice/coding indel) rate against a
background mutation rate estimated from collected
silent mutations [19]. Similarly, driver pathways were
predicted by computing the significance of enrichment
of non-silent mutations in a certain pathway against
background.
Pathway enrichment analysis
Pathway enrichment analyses of genes harboring somatic
SNV, small coding indel, CNV, or SV were performed
using the Gene Set Enrichment Analysis [35,36].
Genomic distribution of somatic mutations
We computed the inter-somatic mutation distance within
individuals by defining the inter-somatic mutation dis-
tance as the distance from a somatic mutation to the very
next one. We computed null distributions by randomly
sampling positions from the genome (excluding assembly
gaps), while maintaining the number of somatic mutations
per chromosome [37]. Using the Kolmogorov–Smirnov
test, we calculated the differences between real distribu-
tions and corresponding null distributions and found
that inter-somatic mutation distances were significantly
smaller than expected (p < 0.05). The distribution of
inter-somatic mutation distance in primary and meta-
static tumors of sample D473 were compared to the dis-
tributions of inter-somatic mutation distances in HCC
and other types of tumors, using published data down-
loaded from ICGC (ftp://data.dcc.icgc.org/version_11/).
We used 2 lung adenocarcinoma samples, TCGA-05-4382-
01A-01D-1265-08 and TCGA-05-4424-01A-22D-1855-08,
from TCGA (http://cancergenome.nih.gov/), 2 prostate
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from OICR (http://oicr.on.ca/), 2 liver cancers, HCC122T
and RK020_C01, from NCC (http://www.ncc.go.jp/en/),
and 1 liver cancer sample (sample 180) sample, sample180,
from a collaboration HCC project of which some results
have been published [11].Data access
Sequencing data for this publication has been deposited
in NCBI Short Reads Archive and is accessible through
accession number SRA076160.
Written informed consent was obtained from the pa-
tient (who was not deceased at the time of writing or
waived by the IRB if deceased) for the publication of this
report and any accompanying images.
Additional files
Additional file 1: Contains tables of summaries of variants, variant
lists, gene lists and pathway lists.
Additional file 2: Contains figures of clinical images and variants.
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